Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that NBN pathogenic variants status confers therapeutic sensitivity to Enzalutamide, Talazoparib in patients with Prostate Adenocarcinoma.
The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
This statement is based on a regulatory approval from the Food and Drug Administration:
TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).